AIM:To assess the hepatitis B virus(HBV)-DNA and the prevalence of occult HBV infection in end-stage renal failure(ESRF)patients from Central Greece. METHODS:Sera from 366 ESRF patients attending five out of six dialy...AIM:To assess the hepatitis B virus(HBV)-DNA and the prevalence of occult HBV infection in end-stage renal failure(ESRF)patients from Central Greece. METHODS:Sera from 366 ESRF patients attending five out of six dialysis units from Central Greece were investigated for HBV-DNA by real-time polymerase chain reaction.Only serum samples with repeatedly detectable HBV-DNA were considered positive.IgG antibodies to hepatitis C virus(anti-HCV)were tested by a third generation enzyme linked immunosorbent assay(ELISA),while IgG antibodies to hepatitis E virus (anti-HEV)were tested by two commercially available ELISAs.RESULTS:HBV-DNA was detected in 15/366 patient (4.1%)and HBsAg in 20/366(5.5%).The prevalenc of occult HBV infection was 0.9%(3/346 HBsAg negative patients).Occult HBV was not associate with a specific marker of HBV infection or anti-HCV o anti-HEV reactivity.There was no significant differenc in HBV-DNA titres,demographic and biochemica features,between patients with occult HBV infectio and those with HBsAg-positive chronic HBV infection. CONCLUSION:In central Greece,4%of ESRF patient had detectable HBV-DNA,though in this setting,th prevalence of occult HBV seems to be very low(0.9%).展开更多
Objective：To investigate the effects of Salvia Miltiorrhiza Liguspyragine Hydrochloride and Glucose Injection（参芎葡萄糖注射液,SLGI） on the expression of platelet membrane receptors proteinase-activated receptor-1...Objective：To investigate the effects of Salvia Miltiorrhiza Liguspyragine Hydrochloride and Glucose Injection（参芎葡萄糖注射液,SLGI） on the expression of platelet membrane receptors proteinase-activated receptor-1（PAR1） and proteinase-activated receptor-4（PAR4） in end-stage renal disease（ESRD） patients on chronic haemodialysis（HD）.Methods：Eighty-six ESRD patients on HD（treated group） were treated with SLGI,7 days as one therapeutic course,for two successive courses.The previous therapies were unchanged.Flow cytometry was used to assess the expression of platelet PAR1 and PAR4 in the patients,and turbidity method was used to determine the platelet maximum aggregation rate（MAR）.Meanwhile,renal function was measured.The final data were compared with those before treatment and with those in the normal control group（54 healthy subjects）.Results：Compared with the normal control group,the expressions of PAR1 and PAR4 and platelet MAR in ESRD patients on HD was significantly higher before treatment（P=0.001,P=0.006, and P=0.008）;after treatment with SLGI,the above indices in patients were remarkably decreased（P=0.036 and P=0.046）,except PAR4（P=0.067）,but still higher than those in the normal control group,however,it was not statistically significant.Conclusions：（1） The overexpression of PAR1 and PAR4 might lead to increased platelet aggregation and this could be one of the reasons for the thrombotic events in ESRD patients on HD.（2） SLGI was able to down-regulate the expression of PAR1 in ESRD patients on HD,improve platelet function,and regulate platelet activation.展开更多
基金Supported by Gilead Sciences Hellas Ltd.partially
文摘AIM:To assess the hepatitis B virus(HBV)-DNA and the prevalence of occult HBV infection in end-stage renal failure(ESRF)patients from Central Greece. METHODS:Sera from 366 ESRF patients attending five out of six dialysis units from Central Greece were investigated for HBV-DNA by real-time polymerase chain reaction.Only serum samples with repeatedly detectable HBV-DNA were considered positive.IgG antibodies to hepatitis C virus(anti-HCV)were tested by a third generation enzyme linked immunosorbent assay(ELISA),while IgG antibodies to hepatitis E virus (anti-HEV)were tested by two commercially available ELISAs.RESULTS:HBV-DNA was detected in 15/366 patient (4.1%)and HBsAg in 20/366(5.5%).The prevalenc of occult HBV infection was 0.9%(3/346 HBsAg negative patients).Occult HBV was not associate with a specific marker of HBV infection or anti-HCV o anti-HEV reactivity.There was no significant differenc in HBV-DNA titres,demographic and biochemica features,between patients with occult HBV infectio and those with HBsAg-positive chronic HBV infection. CONCLUSION:In central Greece,4%of ESRF patient had detectable HBV-DNA,though in this setting,th prevalence of occult HBV seems to be very low(0.9%).
基金Supported by the National Natural Science Foundation of China (No.30572441)
文摘Objective：To investigate the effects of Salvia Miltiorrhiza Liguspyragine Hydrochloride and Glucose Injection（参芎葡萄糖注射液,SLGI） on the expression of platelet membrane receptors proteinase-activated receptor-1（PAR1） and proteinase-activated receptor-4（PAR4） in end-stage renal disease（ESRD） patients on chronic haemodialysis（HD）.Methods：Eighty-six ESRD patients on HD（treated group） were treated with SLGI,7 days as one therapeutic course,for two successive courses.The previous therapies were unchanged.Flow cytometry was used to assess the expression of platelet PAR1 and PAR4 in the patients,and turbidity method was used to determine the platelet maximum aggregation rate（MAR）.Meanwhile,renal function was measured.The final data were compared with those before treatment and with those in the normal control group（54 healthy subjects）.Results：Compared with the normal control group,the expressions of PAR1 and PAR4 and platelet MAR in ESRD patients on HD was significantly higher before treatment（P=0.001,P=0.006, and P=0.008）;after treatment with SLGI,the above indices in patients were remarkably decreased（P=0.036 and P=0.046）,except PAR4（P=0.067）,but still higher than those in the normal control group,however,it was not statistically significant.Conclusions：（1） The overexpression of PAR1 and PAR4 might lead to increased platelet aggregation and this could be one of the reasons for the thrombotic events in ESRD patients on HD.（2） SLGI was able to down-regulate the expression of PAR1 in ESRD patients on HD,improve platelet function,and regulate platelet activation.
